Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of HB0034 in Healthy Adults
NCT05460455Phase 1Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0034 in generalized pustular psoriasis (GPP) (3 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of subjects with drug related adverse events up to 2000 hours. Started Oct 2022; status: completed.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05460455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460455.